Radnostix, Inc. manufactures radioisotope-focused products for medical, industrial and research applications and trades on the OTCQB under INIS. The company, formerly International Isotopes Inc., supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism and thyroid cancer, provides contract drug manufacturing and radioisotope API supply for theranostics clients, and sells calibration and reference standards for nuclear pharmacies, SPECT/PET imaging systems and industrial users through RadQual.
Recurring updates cover operating and financial results across Theranostics Products, Calibration & Reference Products, Nuclear Medicine Standards, Medical Devices and Cobalt Products, along with raw-material supply conditions, product-line updates for EasyFill and RadVent, and the completed corporate rebrand to Radnostix.
International Isotopes Inc. (OTCQB: INIS) reported financial results for Q2 and the first half of 2020. Q2 revenue rose by 1% to $2,159,559, but six-month revenue fell 4% to $4,495,345 due to COVID-19 impacts. Gross profit increased by 8% for Q2 and 1% for H1. Operating expenses rose by 8% in Q2 and 15% in H1, driven by staffing for new product development. Notable is a net income of $229,328 in Q2, up from a net loss of $1,157,194 in 2019. However, revenue from nuclear medicine products and radiological services decreased significantly due to the pandemic.